Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I open-label dose-escalation study of MSC1936369B in advanced solid tumors
NL-OMON36297Phase 1Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pimasertib in Nonhematologic neoplasms, melanoma and cutaneous malignancy, sponsored by Merck & Co. Primary endpoints: Dose-limiting toxicity during cycle 1 and Maximum tolerated dose. Started Sep 2011; status: active, not recruiting.
02
Drugs
pimasertib
03
Conditions
Nonhematologic neoplasmsmelanomacutaneous malignancy
Beyond the preview
Go deeper on NL-OMON36297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36297.